Riskpilot← Back to searchSign inGet full accessAnkrin Therapeutics ApS
APSBankruptCVR 39788705Nordre Fasanvej 215Research and experimental development on natural sciences and engineering · NACE 7210Est. 20184 employees
Revenue 2023
DKK -498K
-51% vs 2022
EBITDA margin
420.1%
+35% vs 2022
Equity ratio
-419.9%
Financial strength
Net profit 2023
DKK -2,3M
+15% vs 2022
| Revenue | DKK -498K | -51% |
| EBITDA | DKK -2,1M | +35% |
| Net profit | DKK -2,3M | +15% |
| Total assets | DKK 1,6M | -56% |
| Equity | DKK -6,8M | -53% |
| Employees | 4 | — |
Legal name
Ankrin Therapeutics ApS
CVR number
39788705
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
16. august 2018
Share capital
DKK 40.000
Employees
4 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af hele direktionen i forening, bestyrelsesformanden og to direktører i forening eller af hele bestyrelsen.
Address
Nordre Fasanvej 215
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | -3.755 | -2.067 | -2.427 | -1.025 | -498 |
| Staff expenses | -1.246 | -1.827 | -2.725 | -2.184 | -1.594 |
| EBITDA | -5.002 | -3.894 | -5.153 | -3.209 | -2.092 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -5.002 | -3.894 | -5.153 | -3.209 | -2.092 |
| Net financials | -357 | -448 | -390 | -294 | -594 |
| Profit before tax | -5.359 | -4.342 | -5.543 | -3.503 | -2.686 |
| Tax | -966 | -857 | -1.049 | -771 | -351 |
| Net profit | -4.393 | -3.485 | -4.493 | -2.733 | -2.334 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 4.425 | 10.714 | 6.579 | 3.656 | 1.614 |
| Equity | -4.378 | 2.781 | -1.712 | -4.445 | -6.779 |
| Long-term debt | 7.877 | 6.965 | 7.300 | 7.563 | 8.108 |
| Short-term debt | 926 | 968 | 991 | 538 | 286 |
| Total debt | 8.803 | 7.933 | 8.291 | 8.101 | 8.394 |
EBITDA margin
-209215200.0%
This company
15.8%
Market median
-1324146935% vs market
20192023
Equity ratio
-419.9%
This company
38.2%
Market median
-1199% vs market
20192023
Return on equity
-233445800.0%
This company
18.4%
Market median
-1268727274% vs market
20192023
Net profit margin
-233445800.0%
This company
8.1%
Market median
-2882047014% vs market
20192023
Asset turnover
-0.31×
This company
1.12×
Market median
-128% vs market
20192023
Debt / equity
1.24×
This company
0.62×
Market median
-100% vs market
20192023
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-08-16 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
TM Management | Management | 2018 – 2025 |
AG Management | Management | 2018 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Chairman | 2020 – 2021 | |
| Chairman | 2021 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33–49.99% | 33.33–49.99% | 2019 | |
| Company | 25–33.32% | 25–33.32% | 2019 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Ankrin Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Michael Frimurer | Management | 0 companies |
| Anja Groth | Management | 0 companies |
| Ulrik Svane Sørensen | Chairman | 0 companies |
| Jimmy Arnold Van heusden | Chairman | 0 companies |